PROFESSIONAL EDITION

The largest community of pharma leaders

Newron Completes Enrollment of Explanatory Safety and Efficacy Study With Evenamide in Schizophrenia Patients

MILAN & MORRISTOWN, N.J.–(BUSINESS WIRE)—- $NWRN #schizophrenia–Newron completes enrollment of explanatory safety and efficacy study with evenamide in schizophrenia patients.

Source Business Wire Health: Pharmaceutical NewsRead More

Recent Articles